Medicine Grand Rounds - Insulin @ 100: A Historical Perspective
Offered By: Dartmouth College via Independent
Course Description
Overview
Dartmouth Health Continuing Education for Professionals Home, Medicine Grand Rounds - Insulin @ 100: A Historical Perspective, 12/3/2021 8:00:00 AM - 12/3/2024 9:00:00 AM, Participants in Medicine Grand Rounds will be able to identify the most current treatment guidelines, innovations, and standards of practice, and apply them to improve the care of individual patients, promote health and wellness in the population, and achieve clinical quality and safety goals. These educational activities are grounded in principles of health equity, evidence based medicine, inter-professional teamwork, patient-centered care, and respect for human dignity.
Presenter
Lee A. Witters, MD
Eugene W. Leonard 1921 Professor of Medicine
Professor of Medical Education and Biochemistry & Cell Biology
Audrey and Theodor Geisel School of Medicine at Dartmouth
Professor of Biological Sciences, Dartmouth College
About our Presenter
Dr. Lee Witters is a graduate of Oberlin College & the University of Rochester Medical School, and completed his post-graduate training in internal medicine and endocrinology and metabolism at the Beth Israel and Massachusetts General Hospitals in Boston and at the National Institutes of Health. He has served on the faculty of Harvard Medical School in the Diabetes Unit at MGH until 1984 when he came to Dartmouth and DHMC, serving as Chief of the Endocrine Section until 2001.
Learning Outcome(s)
Participants will be able to review the history of diabetes mellitus from the impact and discovery of insulin in 1921 to subsequent issues including new insulins, patent protection & cost.
Disclosure
The following activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for this activity have reported the following financial relationship(s)* with ineligible company(ies)**. All of the relevant financial relationships listed for these individuals have been mitigated.
* Richard I. Rothstein, MD ~ has research support from Fractyl and is on the Scientific Advisory Board for Allurion.
Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this activity report NO financial relationship(s)* with any ineligible company(ies)**.
* A “financial relationship" includes employee, researcher (named as the PI), consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and/or an ownership interest (not including stocks owned in a managed portfolio).
** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Bibliographic Material
See presentation for bibliographic sources to allow for further study.
Presenter
Lee A. Witters, MD
Eugene W. Leonard 1921 Professor of Medicine
Professor of Medical Education and Biochemistry & Cell Biology
Audrey and Theodor Geisel School of Medicine at Dartmouth
Professor of Biological Sciences, Dartmouth College
About our Presenter
Dr. Lee Witters is a graduate of Oberlin College & the University of Rochester Medical School, and completed his post-graduate training in internal medicine and endocrinology and metabolism at the Beth Israel and Massachusetts General Hospitals in Boston and at the National Institutes of Health. He has served on the faculty of Harvard Medical School in the Diabetes Unit at MGH until 1984 when he came to Dartmouth and DHMC, serving as Chief of the Endocrine Section until 2001.
Learning Outcome(s)
Participants will be able to review the history of diabetes mellitus from the impact and discovery of insulin in 1921 to subsequent issues including new insulins, patent protection & cost.
Disclosure
The following activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for this activity have reported the following financial relationship(s)* with ineligible company(ies)**. All of the relevant financial relationships listed for these individuals have been mitigated.
* Richard I. Rothstein, MD ~ has research support from Fractyl and is on the Scientific Advisory Board for Allurion.
Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this activity report NO financial relationship(s)* with any ineligible company(ies)**.
* A “financial relationship" includes employee, researcher (named as the PI), consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and/or an ownership interest (not including stocks owned in a managed portfolio).
** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Bibliographic Material
See presentation for bibliographic sources to allow for further study.
Tags
Related Courses
The 16th Ethics Committee Training Day Section Five of Six - Surrogate Decision MakingDartmouth College via Independent The 16th Ethics Committee Training Day - Section One of Six - Common Presentations of Ethical Concerns brought to a Clinical Ethics Committee
Dartmouth College via Independent The 16th Ethics Committee Training Day - Section Three of Six Exploring the Ethical Foundation for Ethics Committees
Dartmouth College via Independent The 16th Ethics Committee Training Day Section Two of Six - What is a Healthcare Ethics Committee
Dartmouth College via Independent The 16th Ethics Committee Training Day Section Four of Six - Informed Consent
Dartmouth College via Independent